Universal Influenza Vaccines 2020

Provisional Conference Programme | Monday 28th September 2020

Welcome to Oxford & Opening Remarks
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘A global perspective on universal influenza vaccines: What do we want and how will we use it?’
Christopher Chadwick, Martin Friede and Ann Moen
(World Health Organization, Geneva, Switzerland)

‘Scientific steps from the Spanish Influenza era have provided a firm foundation for both conventional and exploratory new influenza vaccines’
John S. Oxford and D. Gill
(Blizard Institute, Queen Mary College, London, UK)

‘Achieving better influenza vaccines: Implementation of NIAID's strategic plan for universal influenza vaccine development’
Jennifer Gordon
(Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, HHS, Behesda, Maryland, USA)

‘What is a Universal Influenza Vaccine? Is it possible?’
Rob Lambkin-Williams
(Virology Consult, London, UK)

Coffee Break & Poster Set-Up

SESSION 2:
UNIVERSAL VACCINES

Moderator: John Oxford
(Blizard Institute, Queen Mary College, London, UK)

‘The development of a new approach to influenza vaccination, from concept to efficacy testing’
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Development of a universal influenza vaccine technology landscape’
Julie Ostrowsky
(Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota, USA)

‘Development of universal influenza vaccines in Russia’
Yuri Vasiliev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

Lunch Break & Posters

SESSION 3:
SUBTYPES/EPITOPES

Moderator: Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘From subtype coverage to universal flu vaccines’
Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘Utilising epitopes of limited variability to produce a broadly neutralising influenza vaccine’
Craig P. Thompson^1,2, Uri Obsolski^1,2, Alex Fyfe^1,2, Jose Lourenco^1,2, Daniel O’Connor³, Teresa Lambe⁴, Christine Rollier³, Andrew Pollard³ and Sunetra Gupta^1,2
(¹ Department of Zoology, University of Oxford, Oxford, UK; ² Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; ³ Oxford Vaccine Group, Department of Paediatrics and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; ⁴ Jenner Institute, University of Oxford, Oxford, UK)

‘Targeting highly conserved influenza A and B virus epitopes with nanoparticle-based vaccines’
David F. Zeigler, Emily Gage and Christopher H. Clegg
(TRIA Bioscience Corp, Seattle Washington, USA)

‘Permissive and preferential cell-lines for challenge agent and vaccine manufacture’
Adrian Wildfire
(SGS, Camberley, UK)

Tea Break & Posters

SESSION 4:
STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION

Moderator: To be confirmed

‘Standardisation of serology assays used in the evaluation of vaccines’
Othmar G. Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Correlates of protection for influenza vaccines’
Emanuele Montomoli
(VisMederi SRl, Siena, Italy)